The Cancer Letter

Inside information on cancer research and drug development

In Brief

Zinner elected chair of American College of Surgeons board of regents

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MICHAEL ZINNER was elected chair of the Board of Regents of the American College of Surgeons.

Zinner is a general surgeon with expertise in pancreatic-hepatobiliary diseases. Since 2016, he has been the founding chief executive officer and executive medical director of the Miami Cancer Institute–Baptist Health South Florida.

Prior to that time, he served as surgeon-in-chief and Moseley Professor of Surgery at the Brigham and Women’s Hospital and Harvard Medical School. During this time, Zinner also served as clinical director and chief of surgical services at the Dana-Farber/Brigham and Women’s Cancer Center.

A fellow of the American College of Surgeons (FACS) since 1983, Zinner has previously served as vice-chair of the ACS Board of Regents (2010-2015) and chair of the ACS Board of Governors (2008-2010).

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Sponsored

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
By Saro Armenian
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account